But other similar approaches are on their way: antibodies against killer cell immunoglobulin-like receptors (KIR) and LAG3 are in early phase clinical studies of novel cancer therapies (NCT01968109, clinicaltrials.gov), and further reagents specific for e.g. TIM3 and BTLA are in preclinical development (114, 115). The gene discussed is HAVCR2; the disease is cancer.